We're hosting a satellite symposium onsite at @ESCardio with top cardiologists in the space to discuss the important role of transthyretin in ATTR-CM. Learn more about the program: bit.ly/3yslD6p

We are excited to share the ATTRibute-CM recurrent events analysis in ATTR-CM at the HFSA Annual Scientific Meeting 2024 by Daniel Judge, M.D., professor of medicine and cardiology at the MUSC Health. Learn more: bit.ly/3XHdJhZ

🚀 Elevate your expertise in ATTR-CM at the 3rd International Congress on ATTR Amyloidosis. Interactive, 🧠 expert-led session with Mazen Hanna, Brett Sperry, MD, Saurabh Malhotra and Ronald Witteles. Click here now: ms.spr.ly/6013mmT3B #ICAAlive24

We’re thrilled to share our outcomes data from our long-term open-label extension of ATTRibute-CM, our Phase 3 study of acoramidis in ATTR-CM, in a featured science oral presentation at the 2024 American Heart Association Scientific Sessions. Learn more: bit.ly/4eNw9V8

In honor of World Amyloidosis Day, we hope to raise awareness about how people are impacted by amyloidosis. We believe that by providing education about the condition, we will help eliminate delays in diagnostics for patients. Learn about how to support the amyloidosis community:

GAMEDAY LET’S GO

Join us at #AHA24! We’ll be presenting a featured science presentation on our outcomes data through 42 months from the open-label extension of ATTRibute-CM, our Phase 3 Study of acoramidis for ATTR-CM & three moderated digital poster presentations. bit.ly/4eYVDPW

Happening 12/3! HFSA Education Partner Program: Don't Fail Them Now: Bridging Diagnostic and Treatment Gaps in Transthyretin Cardiac Amyloidosis. Discover More >> bit.ly/3Z7JAtc

Cooper Manning shares his approach to parenting Arch in the era of NIL and the evolving landscape of college football.

ASNC Masterclass: Cardiac Amyloidosis Join Dr. Frederick Ruberg & Dr. Andrew Staron of BU Amyloidosis Center for an expert-led session on the latest in cardiac amyloidosis imaging & management! Learn from top experts in the field!#ASNC 📅 March 7-9, 2025 💻 Virtual Event – Open to All!

It is #AmyloidosisAwarenessMonth #DYK ATTR can impact individuals at any age? Follow along this month as we work to #IlluminateATTR, today and all year long.

🚨 Early diagnosis = better outcomes! Learn to spot clinical signs of ATTR-CM, use biomarkers for precision care, and implement evidence-based management strategies. 🏥 #ACC25 🔗 Secure your spot now: ms.spr.ly/6013qEVtv Nitasha Sarswat

📢 Fellowship Opportunity! Apply Now! 🏥 The Medical University of South Carolina’s Division of Cardiology is now accepting applications for a one-year, non-ACGME Amyloidosis Fellowship. 🔬 Gain specialized clinical & research training in amyloidosis and advance your expertise!

We’re excited to announce that data from the ATTRibute-CM Phase 3 study will be presented at the American College of Cardiology 2025. The data on cardiovascular outcomes in variant and wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) patients will be featured in a flat board poster

Join us this year at @ACCintouch 2025 in Chicago! We’ll be providing new updates on our TTR stabilizer for ATTR-CM as well as supporting an industry expert theater with Medscape. Learn more: investor.bridgebio.com/press-releases #ACC25

This year at @ACCintouch, we met with leaders in cardiology and learned about innovative developments for patients with heart conditions like ATTR-CM. We also had the opportunity to share findings from ATTRibute-CM, our Phase 3 clinical trial for ATTR-CM. #ACC25

In the April #BPS Leadership Blog, Andrew Mardis, Medical Science Liaison, highlights the value of board certification throughout his career, even as he transitioned away from direct patient care. Read his blog here: bpsweb.org/2025/04/28/mai…

Excited to announce the dosing of our first participant in ACT-EARLY, the first-ever primary prevention study for ATTR testing if prophylactic treatment of asymptomatic carriers with acoramidis can delay or prevent disease onset. Learn more: bit.ly/4jPqdhn

1/43 Welcome to this MedX CME on transthyretin amyloid cardiomyopathy (ATTR-CM), including updates in treatment from ACC25, with cardiologist Michelle Kittleson, MD, PhD. Earn credit: link.med-iq.com/57jSxO